Samsung Biologics disclosed on Jan. 13, 2025 that it has signed a contract manufacturing agreement worth more than $1.4 billion with a Europe-based pharmaceutical company. The name of the European company was not disclosed. The agreement is expected to run through December 2030, subject to change, with production to take place at Samsung Biologics’ Songdo, South Korea, manufacturing site. Source: Biopharm International 16/1/2025